CN114847487A - Application of menadione-7 in preparation of product for improving athletic ability and product for improving athletic ability - Google Patents
Application of menadione-7 in preparation of product for improving athletic ability and product for improving athletic ability Download PDFInfo
- Publication number
- CN114847487A CN114847487A CN202210573947.6A CN202210573947A CN114847487A CN 114847487 A CN114847487 A CN 114847487A CN 202210573947 A CN202210573947 A CN 202210573947A CN 114847487 A CN114847487 A CN 114847487A
- Authority
- CN
- China
- Prior art keywords
- product
- menadione
- improving
- muscle
- exercise performance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000386 athletic effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 210000003205 muscle Anatomy 0.000 claims abstract description 50
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000009825 accumulation Methods 0.000 claims abstract description 10
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 10
- 239000004310 lactic acid Substances 0.000 claims abstract description 10
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 8
- 235000009464 menaquinone-7 Nutrition 0.000 claims abstract description 5
- 239000011700 menaquinone-7 Substances 0.000 claims abstract description 5
- RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims description 41
- 239000013589 supplement Substances 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 230000028709 inflammatory response Effects 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 239000008157 edible vegetable oil Substances 0.000 claims description 3
- 230000006676 mitochondrial damage Effects 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 230000002929 anti-fatigue Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000013622 meat product Nutrition 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 abstract description 6
- 230000004071 biological effect Effects 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 235000012711 vitamin K3 Nutrition 0.000 abstract description 3
- 239000011652 vitamin K3 Substances 0.000 abstract description 3
- 229940041603 vitamin k 3 Drugs 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 230000009469 supplementation Effects 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000002027 skeletal muscle Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 238000010201 enrichment analysis Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000011496 sports drink Nutrition 0.000 description 3
- 235000019143 vitamin K2 Nutrition 0.000 description 3
- 239000011728 vitamin K2 Substances 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011676 menaquinone-4 Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000001256 muscle mitochondria Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
- A23L13/428—Addition of flavours, spices, colours, amino acids or their salts, peptides, vitamins, yeast extract or autolysate, nucleic acid or derivatives, organic acidifying agents or their salts or acidogens, sweeteners, e.g. sugars or sugar alcohols; Addition of alcohol-containing products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
- A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Botany (AREA)
- Agronomy & Crop Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to application of menadione-7 in preparation of a product for improving athletic ability and the product for improving the athletic ability, belonging to the technical field of medicines. In order to solve the problem that the prior art is still lack of exploration of more biological effects of menaquinone-7, the invention provides application of menaquinone-7 in preparing a product for improving athletic ability and the product for improving athletic ability. Experiments prove that menadione-7 can improve the exercise capacity of diabetics, sports people and muscle attenuation people by relieving muscle inflammatory reaction, relieving lactic acid accumulation, improving mitochondrial injury and strengthening mitochondrial energy utilization to enhance muscle strength and muscle mass. The invention provides a plurality of menadione-7 supplementary forms, enriches application scenes and addition strategies, reduces the intervention frequency of products for improving the motor ability, can improve the compliance of a replenisher, and better exerts the biological effect of menadione.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of menadione-7 in preparation of a product for improving athletic ability and the product for improving the athletic ability.
Background
Exercise capacity refers to the ability to perform a series of complex limb movements by consuming energy, which is harnessed by muscle tissue. Muscle cells are rich in mitochondria and glycogen, which can be used efficiently and store energy. Muscle is an important organ for glycolipid metabolism as a tissue in which energy metabolism is vigorous.
In diabetic patients, especially in type 2 diabetic patients, insulin resistance is widely existed in vivo, so that the ability of each tissue and organ to absorb and utilize glucose is reduced, the problem of the ability of muscle tissue to utilize glycolipid is often caused, the phenomenon of muscle strength reduction and even atrophy is commonly existed in diabetic patients, and the exercise ability of the patients is influenced. While branched chain amino acids that help support muscle synthesis further promote insulin resistance and reduce the oxidative capacity of muscle mitochondria, there is a great need for a safer and more effective way to assist in restoring muscle strength without affecting glycemic control in diabetics.
Meanwhile, for the general population of strength exercise, especially for high strength exercise, the effect of muscle fiber destruction and stimulation of regrowth is very significant. Although the destruction of muscle fibers and stimulation of muscle fiber growth are effective ways to increase muscle mass and strength, inflammatory responses can be triggered during the destruction of muscle fibers, such as lactic acid produced in anaerobic exercise, and repair of damaged muscle fibers. This is a self-repair process of the body, but this process takes a certain time to relieve, and the process is accompanied by a certain degree of pain and other reactions, which also affect the motor ability. The sports supplements on the market at present are sports drinks and protein products, aim to supplement electrolytes required by human bodies or promote muscle synthesis, focus on maintaining body fluid balance and accelerating muscle growth, and lack effective components to accelerate and relieve inflammatory reaction in the aspect of muscle recovery.
Vitamin K2 is also called menadione, is a fat-soluble vitamin, and previous researches show that various subtypes of vitamin K2, mainly menadione-4 (MK-4) and menadione-7 (MK-7) are beneficial to bone and cardiovascular health. However, the vitamin K2 of different subtypes has different absorption and operation in the body, and has different bioavailability and effective use level, so the use is different. In the existing products, menadione-7 is used for osteoporosis, improving artery calcification, treating Parkinson and the like, while menadione-4 can only be used for osteoporosis.
The existing menadione-7 products in the market and scientific research aiming at menadione-7 are only limited in the fields of bones, cardiovascular diseases and blood coagulation functions, the structural characteristics of menadione-7 are not fully considered, and the full exploration on more related tissues and organs for the biological effect of menadione-7 is lacked.
Disclosure of Invention
In order to solve the problem that the prior art is still lack of exploration of more biological effects of menaquinone-7, the invention provides application of menaquinone-7 in preparing a product for improving athletic ability and the product for improving athletic ability.
The technical scheme of the invention is as follows:
the application of menadione-7 in preparing products for improving athletic ability.
Further, the product can improve the exercise ability by enhancing the muscle strength and the muscle mass through menadione-7.
Further, the enhancement of muscle strength and muscle mass is achieved by menadione-7 alleviating muscle inflammatory responses, alleviating lactic acid accumulation, improving mitochondrial damage and enhancing mitochondrial energy utilization.
Further, the application is directed to diabetic patients, sports people and people with muscle attenuation.
A product for improving exercise performance, comprising an effective amount of menadione-7.
Further, the effective dose of the menadione-7 is 50ug/kg body weight to 2mg/kg body weight.
Further, the product is a medicine, food or health product.
Furthermore, the medicine also comprises a pharmaceutically acceptable carrier or auxiliary material.
Further, the food is a dairy product, edible oil, a bean product, a meat product or an egg product.
Further, the health care product is a sports supplement, a sports beverage or an anti-fatigue functional beverage.
The invention has the beneficial effects that:
experiments prove that menadione-7 can enhance muscle strength and muscle mass by relieving muscle inflammatory reaction, relieving lactic acid accumulation, improving mitochondrial damage and strengthening mitochondrial energy utilization, thereby improving the exercise capacity of diabetics, sports people and muscle attenuation people, and providing an effective nutrient selection for improving muscle, mitochondria, inflammation, energy utilization and diabetes. The invention provides a plurality of menadione-7 supplementary forms, such as dairy products, edible oil, sports drinks convenient to take and the like which can bring good absorption effect, greatly enriches the application scenes and the adding strategies of menadione-7, and provides more favorable evidences for widely applying menadione-7. The invention applies menadione-7 to the preparation of products for improving the athletic ability, fully utilizes the characteristics of long half-life period and wide in vivo distribution range of menadione-7, not only reduces the intervention frequency of the products for improving the athletic ability, but also can improve the compliance of a replenisher and better exert the biological effect of menadione.
Drawings
FIG. 1 is a graph comparing the ALT levels in sera obtained in example 2;
FIG. 2 is a graph showing the comparison of the AST content in the serum obtained by the measurement in example 2;
FIG. 3 is a comparison of the Cr content in the serum obtained by the measurement in example 2;
FIG. 4 is a graph comparing the CK content in the sera measured in example 2;
FIG. 5 is a graph comparing the LDH content in the sera obtained by the test of example 2;
FIG. 6 is a graph comparing the IL-6 levels in serum obtained by the assay of example 2;
FIG. 7 is a graph comparing the levels of TNF in serum obtained by the assay of example 2;
FIG. 8 is a graph comparing the change in body weight of mice in different dose groups of example 3;
FIG. 9 is a graph comparing the change in food intake of mice in different dose groups of example 3;
FIG. 10 is a graph of the change in gavage amount of mice from different dose groups of example 3;
FIG. 11 is a tSNE plot of skeletal muscle samples from mice of different dose groups of example 3;
figure 12 is a high-grade volcano plot of the low dose supplement group compared to the control group of example 3;
figure 13 is a high-grade volcano plot of the high dose supplementation group compared to the control group of example 3;
figure 14 is a high-level volcano plot comparing the high dose supplementation group to the low dose supplementation group of example 3;
FIG. 15 is a GO enrichment analysis bar graph comparing differential genes for the low dose supplementation group and the control group of example 3;
FIG. 16 is a GO enrichment analysis bar graph comparing differential genes for the high dose supplementation group and the control group of example 3;
figure 17 is a bar graph of GO enrichment analysis of differential genes in the high dose supplementation group compared to the low dose supplementation group of example 3.
Detailed Description
The technical solutions of the present invention are further described below with reference to the following examples, but the present invention is not limited thereto, and any modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention. The process equipment or apparatus not specifically mentioned in the following examples are conventional in the art, and if not specifically mentioned, the raw materials and the like used in the examples of the present invention are commercially available; unless otherwise specified, the technical means used in the examples of the present invention are conventional means well known to those skilled in the art.
Example 1
The embodiment provides a product for improving the exercise capacity by adding menadione-7 into yoghourt, and researches the improvement condition of the exercise capacity of a type 2 diabetes patient by long-term supplementation of the product through the change of muscle strength and muscle mass.
The formula of the product for improving the exercise capacity comprises the following components: yogurt 100 g/cup, and 90ug menadione-7.
Grouping the crowds: the total 102 tested people are patients diagnosed as type 2 diabetes by hospital diagnosis, the age is 50-80 years old, 55 male subjects and 47 female subjects are included, and all the subjects are randomly divided into 2 groups, wherein 56 subjects are supplemented and 46 subjects are controlled. The subjects in each group have no significant difference in terms of age, disease condition, disease course and the like through statistical treatment and are comparable.
Supplementary group: yogurt is 100 g/cup/day, and 90ug menadione-7 is added;
control group: yogurt 100 g/cup day.
Intervention duration: 6 months old
Index detection: muscle strength, muscle mass, physical activity. During the measurement process, the testee wears clothes which are thin and do not influence the measurement result, takes off the shoes and the socks, and takes off all accessories which possibly influence the result.
The detection method comprises the following steps:
muscle strength: the hand grip is usually used for expressing, a trained worker measures by using a calibrated hand grip, all testees keep sitting postures, feet are naturally placed on the ground, knees are bent, buttocks are bent by 90 degrees, shoulders are fixedly retracted, elbow joints are bent by 90 degrees, forearms are neutral, wrist joints are bent by 0-30 degrees, an inertial hand is used for keeping a deviation of 0-15 degrees, the size of a dynamometer handle is set according to the comfort degree of the testees when the testees grip the handle, each participant undergoes three tests, and the average value of the tests is used for analysis.
Muscle mass: rapid measurement of human muscle mass using bioelectrical impedance analyzers, typically ASMI (muscle Mass/height) 2 ) To correct for the effects of height.
Physical activity ability: usually, the gait speed is 6 meters, a professional timer is used for timing, and the testee needs to walk twice for 6 meters, and the average value of the two test times is taken.
The experimental results are as follows:
before intervention, muscle strength, muscle mass, 6 m pace and ASMI were not different between the supplementation and control groups, and baseline measurements for each index are shown in table 1. The amount of change in the various indicators of muscle strength, muscle mass, 6 m pace, and ASMI between the supplementation and control groups after 6 months of menadione-7 intervention as compared to those before intervention is shown in table 2.
TABLE 1
TABLE 2
The data in table 2 show that the muscle strength rise was more pronounced in the supplemented group and was statistically significant between the two groups (P ═ 0.035). Although the muscle mass was not statistically different, it was observed that the muscle mass of the supplemented group was higher than that of the control group. Similarly, height-corrected ASMI index was statistically significant between the two groups (P ═ 0.039).
It can be seen that the muscle strength and muscle mass of the type 2 diabetic are moderately but obviously improved by the long-term supplementation of menadione-7 reinforced yoghurt, which provides a proper protection mode for the reduction of the exercise capacity of the type 2 diabetic.
Example 2
This example provides a product for improving exercise ability by adding menadione-7 to a sports supplement, and the improvement of the product on the exercise ability indirectly improved by the body recovery efficiency is examined through the change of high inflammation level of the body caused by high-intensity exercise.
The formula of the product for improving exercise ability is shown in table 3.
TABLE 3
Grouping the crowds: 90 healthy volunteers aged 20-40 years, wherein 45 male subjects and 45 female subjects were randomly and evenly divided into 3 groups, a glucose intake group, a menadione-7 supplement intake group and a menadione-7 supplement intake group, and 30 subjects were taken.
Intervention duration: the volunteers stay overnight on an empty stomach, arrive at the appointed place on an empty stomach the next morning, carry out three-kilometer running test after taking 500mL of the drink according to groups, take blood before exercise, 0 hour after exercise and 24 hours after exercise, and detect biochemical indexes.
Index detection: serum biochemical data
The experimental results are as follows:
FIGS. 1-7 are graphs comparing the levels of ALT, AST, Cr, CK, LDH, IL-6 and TNF in serum obtained by the assay of example 2; the comparison of AST and ALT contents shows that whether menadione-7 is added or not has insignificant improvement effect on the liver function after exercise; however, the comparison of Cr content shows that the addition of menadione-7 can significantly reduce the accumulation of serum creatinine after exercise. CK is an index reflecting muscle injury after exercise, and the addition of menadione-7 has the tendency of reducing CK after exercise; the LDH content comparison shows that the accumulation of serum lactate dehydrogenase after exercise can be obviously reduced by adding menadione-7, and the menadione-7 can relieve the accumulation of lactate brought by exercise. As can be seen from the comparison of the contents of interleukin 6IL-6 and tumor necrosis factor TNF, the addition of menadione-7 can significantly reduce the level of serum inflammatory factors after exercise.
It can be seen that the level of lactic acid accumulation and the level of inflammation in the body of the medium and high intensity sportsmen are moderately but significantly alleviated by the menadione-7 fortified sports supplement, which provides a suitable protection for the recovery of the sportsmen's exercise capacity.
Example 3
In the embodiment, the gene expression condition of mouse skeletal muscle tissues can be obviously changed through the mixed oil supplement enhanced by different dosages of menadione-7, and the improvement condition of menadione-7 on the motor ability is investigated through improving the accumulation of lactic acid, the utilization of mitochondrial energy and the reduction of inflammatory reaction.
Grouping experiments: 15 sterile C57BL/6N normal mice are averagely divided into a control group, a low-dose menadione-7 oil agent supplement group and a high-dose menadione-7 oil agent supplement group according to a random grouping principle.
Intervention duration: performing intragastric administration once every other day, wherein the intragastric volumes of the three groups are the same, and NC in a control group is blank oil, LOW in a LOW-dose group is as follows: menadione-7 was administered at a dose of 50ug/kg body weight, HIGH dose group HIGH: menadione-7 was gavage at 2mg/kg body weight, the experiment lasted five weeks, and the sterile mice were sacrificed after the end of five weeks.
Index detection: transcriptome sequencing of skeletal muscle tissue.
The experimental results are as follows:
FIGS. 8-10 are graphs comparing the change in body weight, food intake and gavage of mice in different dose groups according to this example; it can be seen that the body weight, food intake and gavage of the mice did not show significant differences during the experimental intervention.
FIG. 11 is a tSNE plot of skeletal muscle samples from mice of different dose groups according to this example; the pictures show that for transcriptome data, low-dose supplementation group individuals are obviously distinguished from control group individuals, and high-dose supplementation group individuals are uniformly distributed in the low-dose supplementation group and the control group, so that the distinguishing degree is not obvious.
FIG. 12 is a high-grade volcano plot of the low dose supplementation group of the present example compared to the control group; blue is a gene whose expression level is lower than that of the control group, and red is a gene whose expression level is higher than that of the control group. FIG. 13 is a high-grade volcano plot of the high dose supplementation group of the present example compared to the control group; blue is a gene whose expression level is lower than that of the control group, and red is a gene whose expression level is higher than that of the control group. FIG. 14 is a high-level volcanic plot comparing the high-dose supplementation group and the low-dose supplementation group of the present example; blue is a gene whose expression level is lower than that of the control group, and red is a gene whose expression level is higher than that of the control group.
In conclusion, the situation of different genes shows that the supplement of the menadione-7 reinforced blending oil agent with high and low doses can bring remarkable gene level change for skeletal muscle. In addition, there is a significant gap in the variation in gene levels with different doses.
FIG. 15 is a bar graph of GO enrichment analysis of differential genes comparing the low dose supplementation groups with the control group according to this example; the pictures show that the low dose supplementation group compared to the control group is associated with lactic acid oxidation, glycolysis processes and immunoreaction processes in skeletal muscle sites.
FIG. 16 is a bar graph of GO enrichment analysis of differential genes comparing the high dose supplementation group with the control group according to this example; the pictures show that the high dose supplementation group was associated with enhanced oxygen transport, inflammatory response, and immune response at skeletal muscle sites compared to the control group.
Fig. 17 is a bar graph of GO enrichment analysis of differential genes comparing the high and low dose supplementation groups of this example, showing that the high and low dose supplementation groups correlate with improved blood circulation, energy metabolism, skeletal muscle structure and immune response at skeletal muscle sites.
By combining the results of the gene function enrichment analysis, the menadione-7 has wide effects on skeletal muscle tissues, including mitochondrial energy utilization (energy metabolism related functions, oxygen transportation), immune response (inflammatory oxidative stress phenomenon) and lactic acid metabolism related functions. The potential efficacy of menadione-7 on skeletal muscle tissue and the dose response relationship that may exist can be seen.
Through three experiments, the invention clarifies the potential effect of menadione-7 in three forms (yoghourt, sports drink and blend oil) on improving the exercise ability brought by multi-level people (diabetics, sports personnel and muscle attenuation people) or animals, including relieving the inflammatory injury of muscles, improving the lactic acid accumulation of the muscles, enhancing the visual ability of the strength and quality of the muscles and the potential capabilities of mitochondrial repair and energy utilization.
Claims (10)
1. The application of menadione-7 in preparing products for improving athletic ability.
2. Use of menadione-7 in the preparation of a product for improving exercise performance in accordance with claim 1, wherein said product achieves an improvement in exercise performance through the enhancement of muscle strength and muscle mass by menadione-7.
3. Use of menadione-7 in the preparation of a product for improving exercise performance according to claim 2, wherein the enhancement of muscle strength and muscle mass is achieved by menadione-7 alleviating muscle inflammatory responses, alleviating lactic acid accumulation, ameliorating mitochondrial damage and enhancing mitochondrial energy utilization.
4. Use of menadione-7 in the manufacture of a product for improving exercise performance in accordance with claim 3, wherein said use is in patients with diabetes, sports persons and people with muscle wasting.
5. A product for improving exercise performance, comprising an effective amount of menaquinone-7.
6. The exercise performance improving product according to claim 5, wherein the effective amount of menadione-7 is 50ug/kg body weight to 2mg/kg body weight.
7. A product for improving exercise performance according to claim 5 or 6, wherein the product is a pharmaceutical, food or health product.
8. The exercise performance improving product according to claim 7, wherein the pharmaceutical product further comprises a pharmaceutically acceptable carrier or excipient.
9. The exercise performance improving product according to claim 7, wherein the food is a dairy product, an edible oil, a bean product, a meat product, or an egg product.
10. The exercise performance improving product according to claim 7, wherein the health product is an exercise supplement, an exercise drink or an anti-fatigue functional drink.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210573947.6A CN114847487A (en) | 2022-05-24 | 2022-05-24 | Application of menadione-7 in preparation of product for improving athletic ability and product for improving athletic ability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210573947.6A CN114847487A (en) | 2022-05-24 | 2022-05-24 | Application of menadione-7 in preparation of product for improving athletic ability and product for improving athletic ability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114847487A true CN114847487A (en) | 2022-08-05 |
Family
ID=82638584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210573947.6A Pending CN114847487A (en) | 2022-05-24 | 2022-05-24 | Application of menadione-7 in preparation of product for improving athletic ability and product for improving athletic ability |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114847487A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120149780A1 (en) * | 2009-03-12 | 2012-06-14 | Dilip S Mehta | Method of Use of Vitamin K as Energy Enhancer in Diverse Disease States |
| JP2017008002A (en) * | 2015-06-25 | 2017-01-12 | 株式会社東洋新薬 | Anti-fatigue agent |
| CN113889225A (en) * | 2021-10-12 | 2022-01-04 | 南京康兮运动健康科技研究院有限公司 | Method and device for generating sports rehabilitation nutritional meal |
-
2022
- 2022-05-24 CN CN202210573947.6A patent/CN114847487A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120149780A1 (en) * | 2009-03-12 | 2012-06-14 | Dilip S Mehta | Method of Use of Vitamin K as Energy Enhancer in Diverse Disease States |
| JP2017008002A (en) * | 2015-06-25 | 2017-01-12 | 株式会社東洋新薬 | Anti-fatigue agent |
| CN113889225A (en) * | 2021-10-12 | 2022-01-04 | 南京康兮运动健康科技研究院有限公司 | Method and device for generating sports rehabilitation nutritional meal |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Romero-Arenas et al. | Effects of high-resistance circuit training in an elderly population | |
| Castaneda et al. | Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency: a randomized, controlled trial | |
| Kwon et al. | The effects of resistance training on muscle and body fat mass and muscle strength in type 2 diabetic women | |
| Phillips et al. | Resistance training reduces the acute exercise-induced increase in muscle protein turnover | |
| Børsheim et al. | Essential amino acids and muscle protein recovery from resistance exercise | |
| May et al. | Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine | |
| Treuth et al. | Effects of strength training on total and regional body composition in older men | |
| CN102772407B (en) | Pharmaceutical composition for promoting nerve damage restoration and application thereof | |
| Warburton et al. | Cardiovascular health and exercise following spinal cord injury | |
| CN113398144B (en) | Application of nucleotide mixture in preparation of preparation for preventing or relieving sarcopenia of old people | |
| CN103889432B (en) | Muscle mass dose | |
| JP2022548817A (en) | diagnostic method | |
| CRAIG et al. | Chorionic gonadotropin in the treatment of obese women | |
| ABDOUL-LATIF et al. | Effectiveness of a diet for type 2 diabetics based on vegetables and fruits of the Cucurbitaceae family | |
| Ninomiya et al. | Effects of perioperative exercise therapy combined with nutritional supplementation on functional recovery after fast-track total hip arthroplasty | |
| CN114847487A (en) | Application of menadione-7 in preparation of product for improving athletic ability and product for improving athletic ability | |
| Hosseini et al. | Evaluation of Changes in Blood Hematological and Biochemical Parameters in Response to Islamic Fasting and Regular Physical Activity in Male and Female Subjects. | |
| CN114431380A (en) | Protein water suitable for muscle attenuation syndrome and preparation method thereof | |
| WOODRUFF | Vitamin E deficiency in man: biochemical evidence in a patient with xanthomatous biliary cirrhosis | |
| Jung et al. | Comparison of physical fitness, indices of lifestyle disease, and biochemical property of muscle according to sarcopenia and obesity in elderly women | |
| Allen | The Effects of Inertial Load Ergometry Training and Pomegranate Juice Supplementation on Muscle Mass and Aerobic Power in Older Adults | |
| Zafari et al. | The effect of eight weeks of aerobic training and Anethum herbal supplementation on lipid risk factors for cardiovascular disease in inactive obese men | |
| Percival | Examining the effects of deer antler velvet supplementation on muscular strength, performance, and markers of delayed onset muscle soreness | |
| Kakar et al. | Effect of Ascorbic acid on Serum Calcium Levels in Hyperparathyroid and Euparathyroid Individuals with and without Physical Activity | |
| Couvert et al. | Effects of a Cycling versus Running HIIT Program on Fat Mass Loss and Gut Microbiota Composition in Men with Overweight/Obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221012 Address after: 150081 No. 157 health Road, Nangang District, Heilongjiang, Harbin Applicant after: HARBIN MEDICAL University Address before: 150081 Harbin Medical University, No. 157 health care Road, Nangang District, Harbin, Heilongjiang Province Applicant before: Li Ying |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220805 |